
Indegene IPO
- Issue price
- ₹452
- Listing price
- ₹655
- +44.91%
- Current price
- ₹666.2
- +47.39%
- Subscribed
- 70.3x
- Issue size
- ₹1,841.76 Cr
- Listed on
- 13 May 2024
IPO timeline
- Opens6 MayMon
- Closes8 MayWed
- Allotment9 MayThu
- Refunds10 MayFri
- Demat credit10 MayFri
- Listing13 MayMon
Issue details
- Price band
- ₹430 – ₹452 per share
- Issue size
- ₹1,841.76 Cr
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- Fresh capital cum OFS
- Face value
- ₹2 per share
- Lot size
- 33 shares
- Minimum investment
- ₹14,916
- Listing on
- BSE, NSE
- Exchange code
- INDGN · 544172
This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 33 | ₹14,916 |
| Retail (Max) | 13 | 429 | ₹1,93,908 |
| S-HNI (Min) | 14 | 462 | ₹2,08,824 |
| B-HNI (Min) | 68 | 2,244 | ₹10,14,288 |
Reservation
- QIB
- 2,02,35,170 shares (50.00% of the Offer)
- NII
- 60,70,552 shares (15.00% of the Offer)
- Retail
- 1,41,64,620 shares (35.00% of the Offer)
- Employee
- 2,96,208 shares (0.73% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on MUFG Intime India- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 9 May 2024
- Refunds initiated
- 10 May 2024
- Shares credited to demat
- 10 May 2024
- Listing
- 13 May 2024
Grey market premium (GMP)
- Current GMP
- ₹300
- +66.00%
- Estimated listing price
- ₹752
- Issue price ₹452
- Highest
- ₹300
- 12 May
- Lowest
- ₹230
- 7 May
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 12 May 2024 | ₹300 | +66.00% | ₹752 |
| 11 May 2024 | ₹270 | +60.00% | ₹722 |
| 10 May 2024 | ₹270 | +60.00% | ₹722 |
| 9 May 2024 | ₹270 | +60.00% | ₹722 |
| 8 May 2024 | ₹270 | +60.00% | ₹722 |
| 7 May 2024 | ₹230 | +51.00% | ₹682 |
| 6 May 2024 | ₹240 | +53.00% | ₹692 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB192.72x
- NII (HNI)55.91x
- Retail7.86x
- Employee6.62x
Financials
- P/E Ratio
- 33.53
- EPS (₹)
- 13.48
- RoNW
- 18.23%
- PAT Margin
- 12.62%
- Debt / Equity
- 0.30
- NAV (₹)
- 59.86
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 31 Dec 2023 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|---|
| Assets | 2,518.15 | 2,203.87 | 1,353.47 | 596.04 |
| Total Income | 1,969.75 | 2,364.10 | 1,690.50 | 996.92 |
| Profit After Tax | 241.90 | 266.10 | 162.82 | 149.41 |
| NET Worth | 1,327.00 | 1,063.72 | 763.90 | 324.51 |
| Reserves and Surplus | 1,282.65 | 1,019.43 | 763.55 | 324.19 |
| Total Borrowing | 399.33 | 394.34 | 18.24 | 24.76 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Indegene This IPO | ₹1,841.76 Cr | 33.53 | 18.23% | 12.62% | 70.3x | +44.91% |
| Akums Drugs & Pharmaceuticals Mainboard · listed 6 Aug 2024 | ₹1,856.74 Cr | 13580 | -0.57% | 0.02% | 63.44x | +6.77% |
| Symbiotec Pharmalab Mainboard · listed 1 Sep 2026 | ₹1,757 Cr | 56.81 | 9.48% | 12.60% | 71.26x | 0.00% |
| Sagility India Mainboard · listed 12 Nov 2024 | ₹2,106.4 Cr | 61.52 | 0.29% | 11.83% | 3.2x | +3.53% |
| Entero Healthcare Solutions Mainboard · listed 16 Feb 2024 | ₹1,600 Cr | 129.75 | -1.86% | 4.69% | 1.56x | -2.33% |
| Paras Healthcare Mainboard · listed 28 Oct 2026 | ₹1,450 Cr | 37.72 | 11.83% | 10.38% | 2.23x | +3.90% |
| Rubicon Research Mainboard · listed 16 Oct 2025 | ₹1,378 Cr | 46.13 | 29.02% | 10.37% | 109.32x | +27.84% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Indegene plans to use the money raised, as stated in the offer document.
- Repayment/prepaymentof indebtedness of one of the Material Subsidiaries, ILSL Holdings, Inc₹391.34 Cr
- Funding the capital expenditure requirements of the Company and one of the Material Subsidiaries, Indegene, Inc.₹102.92 Cr
- General Corporate Purposes and Inorganic Growth₹230.12 Cr
About Indegene
Indegene Limited was incorporated in India in 1998. It provides digital-led commercialisation services for biopharmaceutical, emerging biotech and medical device companies. Its solutions help with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of products. It combines over two decades of healthcare domain expertise with its technology platforms. As of 31 December 2023 it had 65 active clients, served from six operation hubs and 17 offices across North America, Europe and Asia. Its subsidiary DT Associates offers consulting under the DT Consulting brand. The company has no identifiable promoter. The IPO was Rs 1,841.76 crore, with Rs 760.52 crore of fresh issue and Rs 1,081.24 crore of offer for sale by investors and other shareholders. Rs 391.34 crore was planned for repaying debt of its subsidiary ILSL Holdings and Rs 102.92 crore for capital expenditure.
Strengths
- Total income rose from Rs 996.92 crore in FY2021 to Rs 2,364.10 crore in FY2023.
- Profit after tax rose from Rs 149.41 crore in FY2021 to Rs 266.10 crore in FY2023.
- Profit after tax was Rs 241.90 crore in the nine months to 31 December 2023.
- The source puts the PAT margin at 12.62% and return on net worth at 18.23%.
- Rs 391.34 crore of the fresh issue was planned for repaying subsidiary debt.
Risks
- The pre-issue P/E was 37.78 at the upper band of Rs 452, based on EPS of Rs 11.96.
- Rs 1,081.24 crore of the Rs 1,841.76 crore issue was offer for sale.
- Total borrowing rose from Rs 18.24 crore on 31 March 2022 to Rs 399.33 crore on 31 December 2023.
- It serves only 65 active clients, so the loss of a large client would hurt, and most income is earned abroad in foreign currency.
- The company has no identifiable promoter, and the post-issue market value at Rs 452 was Rs 10,814.07 crore.
Promoters and shareholding
No Identifiable Promoter
Anchor investors
Registrar, lead managers and documents
Lead managers
Documents
Indegene IPO: common questions
1.When does the Indegene IPO open and close?
The Indegene IPO opens on 6 May 2024 and closes on 8 May 2024.
2.What is the price band of the Indegene IPO?
The price band is ₹430 – ₹452 per share, with a lot size of 33 shares and a minimum investment of ₹14,916.
3.What is the size of the Indegene IPO?
The issue size is ₹1,841.76 Cr (Fresh capital cum OFS).
4.What is the GMP of the Indegene IPO?
The last reported grey market premium is ₹300 per share as of 12 May 2024, 12:00 PM IST. GMP is unofficial and changes frequently.
5.When is the Indegene IPO allotment?
The basis of allotment is expected on 9 May 2024. Allotment status can be checked with the registrar, MUFG Intime India Private Limited.
6.When will the Indegene IPO list?
The shares listed on 13 May 2024 on BSE, NSE.
7.Who is the lead manager of the Indegene IPO?
The book running lead managers are Kotak Mahindra Capital Company Limited, JP Morgan India Pvt. Ltd, Citigroup Global Markets India Pvt. Ltd, Nomura Financial Advisory & Securities (India) Pvt. Ltd, and the registrar is MUFG Intime India Private Limited.
8.What will the money raised in the Indegene IPO be used for?
As stated in the offer document, the proceeds are for: Repayment/prepaymentof indebtedness of one of the Material Subsidiaries, ILSL Holdings, Inc; Funding the capital expenditure requirements of the Company and one of the Material Subsidiaries, Indegene, Inc.; General Corporate Purposes and Inorganic Growth.
9.How can my company launch an IPO like Indegene?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393